Cervical cancer is the second most common cancer in women world-wide after breast cancer. Each year, there are approximately 437,000 new cases of invasive cancer of the cervix diagnosed and more than 200,000 women die from the disease, 79% of which occur in developing countries. In the Netherlands approximately 715 new cases of cervical cancer are diagnosed each year with an age-standardised incidence rate of 8,6 new cases per 1 00,000 women. The age-standardised mortality rate for the Netherlands has been estimated at 2,4 deaths per 1 00,000 women with a total of 234 deaths reported in 1995. The average age-standardised mortality rate of developing countries is 2,5 f1mes that of industrialised areas.

, , ,
Dutch Prevention Fund/Zorg Onderzoek Nederland, Digene, Cytyc Europe, 3M Pharma Nederland, Schering Nederland BV, Ferring BV, Organon Nederland BV, Rovers Medical Devices BV, Werkgroep Cervix Uteri
T.J.M. Helmerhorst (Theo) , C.J.L.M. Meijer (Chris)
Erasmus University Rotterdam
hdl.handle.net/1765/23536
Erasmus MC: University Medical Center Rotterdam

Nobbenhuis, M. (2001, October 10). Human papillomavirus and natural history of cervical intraepithelial neoplasia : clinical consequences. Retrieved from http://hdl.handle.net/1765/23536